Population
Patients with short QT syndrome (review of pathophysiology, clinical presentation, and treatment)
Design
Review
Authors
Loading...
Short QT syndrome merits inclusion in sudden-death evaluations; leaves open optimal risk stratification and therapy pending prospective data.
Short QT syndrome is a highly arrhythmogenic genetic disorder requiring aggressive risk stratification, with implantable cardioverter defibrillators as first-line therapy and quinidine showing potential as a targeted pharmacologic treatment.
Ramón Brugada (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: